Collectively, these in vitro findings suggest that liraglutide alleviates ox-LDL-induced endothelial dysfunction through GLP-1R-dependent down-regulation of the LOX-1/NOX4/NF-κB signaling pathway. Here, NOX4 is linked to endothelial dysfunction.